NASDAQ · Healthcare · Biotechnology
Moderna, Inc. (MRNA)
As of Sep 25, 4:00 PM ET, Moderna (MRNA) last traded at $198.88, up 2.08% on the day. Its TickerHum research score is 39/100 (below average). It reported revenue of $2.23B for the twelve months ending 2026-06-30, down 27.6% year over year, with a -149.0% operating margin.
Ratings
- Valuation: 5/100 — Strongest input: price / earnings (ttm) Negative earnings. Weakest: price / sales (ttm) 35.6x.
- Growth: 12/100 — Strongest input: diluted eps growth (ttm, yoy) -6.3 %. Weakest: revenue growth (ttm, yoy) -27.6 %.
- Profitability: 0/100 — Based on operating margin -149.0 %, net margin -141.4 %, return on equity -46.6 %.
- Financial health: 95/100 — Strongest input: cash / long-term debt 2.92. Weakest: current ratio 2.29.
- Momentum: 100/100 — Based on 3-month return +195.6 %, 6-month return +271.3 %, 1-year return +712.1 %, price vs 200-day average +209.5 %.
- Attention: 57/100 — Strongest input: headlines in the last 7 days 41. Weakest: volume vs 3-month average 0.8x.
- Risk: 24/100 — Strongest input: max drawdown (1y) -34.2 %. Weakest: annualised volatility (1y) 127.6 %.
- Data confidence: 90/100 — Strongest input: latest financial period age (days) 66 d. Weakest: quote age (hours) 45 h.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $2.23B | TTM ending 2026-06-30 · 10-Q |
| Revenue growth | -27.6% | TTM ending 2026-06-30 · 10-Q |
| Net income | -$3.15B | TTM ending 2026-06-30 · 10-Q |
| Diluted EPS | -$7.98 | TTM ending 2026-06-30 · 10-Q |
| Operating margin | -149.0% | TTM ending 2026-06-30 · 10-Q |
| Net margin | -141.4% | TTM ending 2026-06-30 · 10-Q |
| Free cash flow | -$1.24B | TTM ending 2026-06-30 · 10-Q |
| Cash | $1.72B | as of 2026-06-30 · 10-Q |
| Long-term debt | $591M | as of 2026-06-30 · 10-Q |
| Debt / equity | 0.09 | as of 2026-06-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0001682852).
Compare Moderna with its closest competitors
- Moderna vs Regeneron Pharmaceuticals (MRNA vs REGN) — Same industry (Biotechnology); market cap 0.93x
- Moderna vs Vertex Pharmaceuticals (MRNA vs VRTX) — Same industry (Biotechnology); market cap 1.7x
- Moderna vs Pfizer (MRNA vs PFE) — Same sector (Healthcare), different industry; market cap 2.1x; shares: vaccines
- Moderna vs Merck & Co. (MRNA vs MRK) — Same sector (Healthcare), different industry; market cap 4.6x; shares: vaccines
- Moderna vs Becton, Dickinson and (MRNA vs BDX) — Same sector (Healthcare), different industry; market cap 0.63x
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.